

Withdrawal/Redaction Sheet

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
001. memo	Chuck Dolan to Reed re: Meeting, September 27th with Genetic Design (partial) (1 page)	9/23/93	P6/b(6)

COLLECTION:

Clinton Presidential Records
 Domestic Policy Council
 Bruce Reed (Subject File)
 OA/Box Number: 21201

FOLDER TITLE:

Child Support-Paternity

rs39

RESTRICTION CODES

Presidential Records Act - {44 U.S.C. 2204(a)}

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PKM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - {5 U.S.C. 552(b)}

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
001. memo	Chuck Dolan to Reed re: Meeting, September 27th with Genetic Design (partial) (1 page)	9/23/93	P6/b(6)

**This marker identifies the original location of the withdrawn item listed above.
For a complete list of items withdrawn from this folder, see the
Withdrawal/Redaction Sheet at the front of the folder.**

COLLECTION:

Clinton Presidential Records:
Domestic Policy Council
Bruce Reed (Subject File)
OA/Box Number: 21201

FOLDER TITLE:

Child Support-Paternity

rs39

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advise between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

MEMORANDUM

*File:
CS - Paternity*

TO: Bruce Reed

FROM: Chuck Dolan *CHD*

DATE: September 23, 1993

RE: Our Meeting on Monday, September 27th, with Genetic Design

Thanks for agreeing to meet with us next Monday (September 27th) at 11:00 am. I am attaching a background sheet on the subject of the meeting as well as bios of Claude Buller and Darryll Grubbs and a description of Genetic Design. Darryll Grubbs represents the Child Support Council.

Participants:	<u>DOB</u>	<u>SS#</u>
Claude L. Buller	8/16/42	[REDACTED]
Darryll W. Grubbs	8/3/52	[REDACTED]
Charles H. Dolan, Jr.	6/12/50	[REDACTED]

*Cleared by
OASIS - 9/2
CM*

CHD:rk

Attachments

**BACKGROUND FOR SEPTEMBER 27 MEETING WITH
GENETIC DESIGN, INC.**

Claude Buller, president of Genetic Design Inc., has requested this meeting to discuss the President's welfare reform proposal as it relates to child support enforcement.

Based in Greensboro, North Carolina, Genetic Design maintains a state-of-the-art testing laboratory that identifies genetic markers to provide objective scientific evidence for a number of purposes, including paternity establishment.

Specifically, Mr. Buller would like to discuss buccal swab technology, a new technology that could be used to enhance the President's child support enforcement efforts. Buccal swab technology is a safe, non-invasive method of collecting DNA. Hospitals are beginning to use this technology as part of voluntary paternity establishment programs that seek to establish paternity within days of a child's birth. This capability can save state agencies months of work attempting to prove paternity and can guarantee that child support payments begin as soon after a child's birth as possible.

In addition, Mr. Buller would like to address the issue of the Federal government's reimbursement practices for paternity testing. Currently, the Federal government reimburses to the states 90 percent of the cost of paternity testing. These funds are generally returned to the states' general funds. Mr. Buller is interested in discussing ways that these funds can be used to reduce the tremendous backlog faced by state agencies by ensuring that these funds are used for paternity establishment programs.

GENETIC DESIGN, INC.

Genetic Design, Inc. (GDI) is a specialty genetic testing laboratory focused on Human Identification, headquartered in Greensboro, North Carolina. Genetic Design provides genetic testing services to child support enforcement agencies, attorneys, courts, law enforcement agencies, and registries for bone marrow transplants located throughout the United States, Asia and Europe.

GDI currently conducts more paternity tests than any other laboratory in the United States and has approximately 39% market share (according to the most recent survey by the American Association of Blood Banks). The Company's bone marrow testing business is one of the largest in the world. GDI serves as the primary typing lab for the largest German donor recruitment center, the American Bone Marrow Registry and performs testing for the National Marrow Donor Program and other international registries. While Forensic DNA Analysis represents a new and developing market for GDI, the company's experience in dealing with the courts and its reputation in paternity and bone marrow testing markets provide a solid base from which to grow its forensic identification testing business.

GDI is the largest volume DNA Analysis laboratory in the world and over twice as large as the closest competitor. The Company is licensed by the United States Department of Health and Human Services and is certified by the American Association of Blood Banks for parentage testing and the American Society of Histocompatibility and Immunogenetics for tissue typing and parentage testing.

GDI is a wholly-owned subsidiary of Integrated Genetics, headquartered in Framingham, Massachusetts. Integrated Genetics, a public corporation and a majority-owned subsidiary of Genzyme Corporation, provides a broad range of genetic testing services to hospitals, clinical laboratories, physicians and health maintenance organizations throughout the United States. Genzyme, located in Cambridge, Massachusetts, is a diversified human health care company with product development, manufacturing and marketing capabilities in biotherapeutic and diagnostic products, pharmaceuticals and fine chemicals, and diagnostic services.



7017 ALBERT PICK ROAD
GREENSBORO, NC 27409-8684

BIOGRAPHY
ON
CLAUDE L. BULLER

Claude L. Buller, President, joined Genetic Design, Inc. (GDI), a genetic testing company, in 1988 where he has coordinated an aggressive strategy which increased annual sales from \$3 million a year in July 1988 to \$15 million in March, 1991. Under Mr. Buller's direction, the Company has been active in technical forums, co-sponsored the Child Support Council, and developed a buccal swab sampling technique for use in paternity testing. As the largest paternity testing lab in the nation, Genetic Design provides paternity testing services to child support enforcement agencies in all fifty (50) states as well as internationally. In addition to paternity testing, GDI also performs bone marrow tissue typing and DNA forensics analysis.

In June of 1992, Genetic Design was acquired by IG Laboratories located in Framingham, Massachusetts. IG applies advanced biotechnology to develop and provide high quality sophisticated genetic testing services to physicians, hospitals, health maintenance organizations and social service agencies throughout the United States. IG Laboratories is a majority-owned of Genzyme Corporation located in Cambridge, Massachusetts.

Mr. Buller has been a presenter at several biotechnology conferences over the past few years, including The Med-Tech Group, Division of D.H. Blair & Co., Inc.'s "Positioning the Healthcare Industry for the 21st Century" in December 1990. In 1990 he was a finalist for the Regional "Entrepreneur of the Year", which honors those who have contributed to or created successful and growing business ventures.

Prior to GDI, Mr. Buller was President and CEO of CompuChem Corporation, an Environmental and Drug Testing Analytical Laboratory. At CompuChem, he grew revenue from \$5 million (1984) to \$40 million in 1988. He managed an IPO in 1985 raising over \$7 million. Prior to CompuChem, Mr. Buller was Chief Operating Officer for the Pfaudler Company, a manufacturing company with operations in five countries. Mr. Buller began his career with the General Electric Company where he held various financial management assignments. He has a B.A. in Economics from Colby College.